vs
Orthofix Medical Inc.（OFIX）与Orion Group Holdings Inc（ORN）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Orion Group Holdings Inc的1.0倍（$219.9M vs $216.3M），Orion Group Holdings Inc净利率更高（2.2% vs -1.0%，领先3.2%），Orion Group Holdings Inc同比增速更快（14.6% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 6.1%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
奥里昂集团是源自芬兰的全球化制药企业，1917年成立，总部位于芬兰埃斯波。公司面向全球市场研发、生产并销售人用与兽用药品以及药用活性成分，旗下全部生产基地与大部分研发部门均设立在芬兰。
OFIX vs ORN — 直观对比
营收规模更大
OFIX
是对方的1.0倍
$216.3M
营收增速更快
ORN
高出12.7%
2.0%
净利率更高
ORN
高出3.2%
-1.0%
两年增速更快
OFIX
近两年复合增速
6.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $216.3M |
| 净利润 | $-2.2M | $4.7M |
| 毛利率 | 71.1% | 12.0% |
| 营业利润率 | 0.2% | — |
| 净利率 | -1.0% | 2.2% |
| 营收同比 | 2.0% | 14.6% |
| 净利润同比 | 92.4% | 435.7% |
| 每股收益（稀释后） | $-0.05 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXORN
| Q1 26 | — | $216.3M | ||
| Q4 25 | $219.9M | $233.2M | ||
| Q3 25 | $205.6M | $225.1M | ||
| Q2 25 | $203.1M | $205.3M | ||
| Q1 25 | $193.6M | $188.7M | ||
| Q4 24 | $215.7M | $216.9M | ||
| Q3 24 | $196.6M | $226.7M | ||
| Q2 24 | $198.6M | $192.2M |
净利润OFIXORN
| Q1 26 | — | $4.7M | ||
| Q4 25 | $-2.2M | $-240.0K | ||
| Q3 25 | $-22.8M | $3.3M | ||
| Q2 25 | $-14.1M | $841.0K | ||
| Q1 25 | $-53.1M | $-1.4M | ||
| Q4 24 | $-29.1M | $6.8M | ||
| Q3 24 | $-27.4M | $4.3M | ||
| Q2 24 | $-33.4M | $-6.6M |
毛利率OFIXORN
| Q1 26 | — | 12.0% | ||
| Q4 25 | 71.1% | 11.6% | ||
| Q3 25 | 72.2% | 13.2% | ||
| Q2 25 | 68.7% | 12.6% | ||
| Q1 25 | 62.8% | 12.2% | ||
| Q4 24 | 69.0% | 14.0% | ||
| Q3 24 | 68.7% | 11.9% | ||
| Q2 24 | 67.8% | 9.5% |
营业利润率OFIXORN
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 2.2% | ||
| Q3 25 | -8.3% | 2.4% | ||
| Q2 25 | -7.9% | 1.7% | ||
| Q1 25 | -25.2% | 0.4% | ||
| Q4 24 | -5.3% | 4.4% | ||
| Q3 24 | -9.6% | 3.4% | ||
| Q2 24 | -12.5% | -1.4% |
净利率OFIXORN
| Q1 26 | — | 2.2% | ||
| Q4 25 | -1.0% | -0.1% | ||
| Q3 25 | -11.1% | 1.5% | ||
| Q2 25 | -6.9% | 0.4% | ||
| Q1 25 | -27.4% | -0.7% | ||
| Q4 24 | -13.5% | 3.1% | ||
| Q3 24 | -13.9% | 1.9% | ||
| Q2 24 | -16.8% | -3.4% |
每股收益（稀释后）OFIXORN
| Q1 26 | — | $0.12 | ||
| Q4 25 | $-0.05 | $-0.00 | ||
| Q3 25 | $-0.57 | $0.08 | ||
| Q2 25 | $-0.36 | $0.02 | ||
| Q1 25 | $-1.35 | $-0.04 | ||
| Q4 24 | $-0.76 | $0.22 | ||
| Q3 24 | $-0.71 | $0.12 | ||
| Q2 24 | $-0.88 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $6.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $166.7M |
| 总资产 | $850.6M | $478.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXORN
| Q1 26 | — | $6.3M | ||
| Q4 25 | $82.0M | $1.6M | ||
| Q3 25 | $62.9M | $4.9M | ||
| Q2 25 | $65.6M | $1.7M | ||
| Q1 25 | $58.0M | $13.0M | ||
| Q4 24 | $83.2M | $28.3M | ||
| Q3 24 | $30.1M | $28.3M | ||
| Q2 24 | $26.4M | $4.8M |
总债务OFIXORN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | $33.4M | ||
| Q1 25 | $156.9M | $23.3M | ||
| Q4 24 | $157.0M | $23.2M | ||
| Q3 24 | $118.5M | $28.0M | ||
| Q2 24 | $118.0M | $60.3M |
股东权益OFIXORN
| Q1 26 | — | $166.7M | ||
| Q4 25 | $450.0M | $159.0M | ||
| Q3 25 | $442.5M | $157.9M | ||
| Q2 25 | $458.3M | $153.2M | ||
| Q1 25 | $458.3M | $150.8M | ||
| Q4 24 | $503.1M | $150.7M | ||
| Q3 24 | $525.9M | $142.4M | ||
| Q2 24 | $546.0M | $111.1M |
总资产OFIXORN
| Q1 26 | — | $478.7M | ||
| Q4 25 | $850.6M | $414.7M | ||
| Q3 25 | $832.6M | $422.4M | ||
| Q2 25 | $837.2M | $432.7M | ||
| Q1 25 | $823.1M | $416.3M | ||
| Q4 24 | $893.3M | $417.3M | ||
| Q3 24 | $867.9M | $430.3M | ||
| Q2 24 | $882.0M | $414.0M |
负债/权益比OFIXORN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | 0.22× | ||
| Q1 25 | 0.34× | 0.15× | ||
| Q4 24 | 0.31× | 0.15× | ||
| Q3 24 | 0.23× | 0.20× | ||
| Q2 24 | 0.22× | 0.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXORN
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $13.8M | ||
| Q3 25 | $12.4M | $23.3M | ||
| Q2 25 | $11.6M | $-5.6M | ||
| Q1 25 | $-18.4M | $-3.4M | ||
| Q4 24 | $23.7M | $13.4M | ||
| Q3 24 | $11.7M | $37.5M | ||
| Q2 24 | $9.0M | $-15.3M |
自由现金流OFIXORN
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $454.0K | ||
| Q3 25 | $2.5M | $13.9M | ||
| Q2 25 | $4.5M | $-12.7M | ||
| Q1 25 | $-25.1M | $-12.5M | ||
| Q4 24 | $15.2M | $9.9M | ||
| Q3 24 | $6.3M | $33.3M | ||
| Q2 24 | $-360.0K | $-20.0M |
自由现金流率OFIXORN
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 0.2% | ||
| Q3 25 | 1.2% | 6.2% | ||
| Q2 25 | 2.2% | -6.2% | ||
| Q1 25 | -13.0% | -6.6% | ||
| Q4 24 | 7.0% | 4.6% | ||
| Q3 24 | 3.2% | 14.7% | ||
| Q2 24 | -0.2% | -10.4% |
资本支出强度OFIXORN
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 5.7% | ||
| Q3 25 | 4.8% | 4.2% | ||
| Q2 25 | 3.5% | 3.5% | ||
| Q1 25 | 3.5% | 4.8% | ||
| Q4 24 | 4.0% | 1.6% | ||
| Q3 24 | 2.7% | 1.8% | ||
| Q2 24 | 4.7% | 2.4% |
现金转化率OFIXORN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 7.05× | ||
| Q2 25 | — | -6.61× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.98× | ||
| Q3 24 | — | 8.79× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
ORN
暂无分部数据
